Research analysts at Citigroup started coverage on shares of Radius Health (NASDAQ:RDUS) in a research report issued on Wednesday. The firm set a “neutral” rating on the biopharmaceutical company’s stock.
RDUS has been the topic of several other reports. Maxim Group restated a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 price objective on shares of Radius Health in a report on Friday, October 6th. Finally, Jefferies Group reduced their price objective on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $51.00.
Shares of Radius Health (NASDAQ RDUS) opened at $27.27 on Wednesday. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 12-month low of $24.66 and a 12-month high of $55.30.
In other news, VP Brent Hatzis-Schoch purchased 1,778 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of $28.09 per share, with a total value of $49,944.02. Following the acquisition, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were purchased at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the acquisition, the insider now directly owns 5,698,799 shares in the company, valued at $149,593,473.75. The disclosure for this purchase can be found here. Insiders have bought a total of 367,678 shares of company stock valued at $11,746,498 over the last ninety days. 15.00% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in Radius Health during the 3rd quarter valued at about $110,000. Sei Investments Co. lifted its holdings in Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the last quarter. Advisor Group Inc. lifted its holdings in Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares during the last quarter. Finally, Blair William & Co. IL bought a new position in Radius Health during the 2nd quarter valued at about $205,000.
TRADEMARK VIOLATION WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/06/radius-health-rdus-research-coverage-started-at-citigroup.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.